Results 51 to 60 of about 3,908,577 (301)

EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1

Nature Communications, 2022
Epstein-Barr virus (EBV) is reportedly the first identified human tumor virus, and is closely related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric carcinoma (GC), and several lymphomas.
Jie Wang, Jun-Shang Ge, Yian Wang, Fang Xiong, Jiayu Guo, Xianjie Jiang, Lishen Zhang, Xiangying Deng, Zhao-Jian Gong, Shan-Shan Zhang, Qijia Yan, Yi He, Xia-Yu Li, Lei Shi, Can Guo, Fuyan Wang, Zheng Li, Ming Zhou, Bo Xiang, Yong Li, W. Xiong, Z. Zeng   +21 more
semanticscholar   +1 more source

Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus [PDF]

, 2007
CD8(+) cytotoxic T-lymphocytes (CTLs) perform a critical role in the immune control of viral infections, including those caused by human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV).
Leigh Brown Andrew J., Sergei L Kosakovsky Pond, Brown, Andrew J. Leigh, Douglas D Richman, Poon Art F. Y, Frost Simon D. W, Richman Douglas D, Poon, Art FY, Brown, Andrew J Leigh, Simon D W Frost, Leigh Brown, Andrew J., Frost, Simon D. W., Kosakovsky Pond Sergei L., Pond, Sergei L Kosakovsky, Art F Y Poon, Andrew J Leigh Brown, Richman, Douglas D., Richman, Douglas D, Pond, Sergei L. Kosakovsky, Frost, Simon DW, Bennett, Phil, Phil Bennett, Bennett Phil, Poon, Art F. Y.   +23 more
core   +1 more source

Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

Frontiers in Immunology, 2020
Growth/differentiation factor-15 (GDF-15), also named macrophage inhibitory cytokine-1, is a divergent member of the transforming growth factor β superfamily.
Jörg Wischhusen, Ignacio Melero, Ignacio Melero, Ignacio Melero, Wolf Herman Fridman   +4 more
doaj   +1 more source

PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation

Cell Death and Disease, 2023
Necroptosis plays a double-edged sword role in necroptotic cancer cell death and tumor immune escape. How cancer orchestrates necroptosis with immune escape and tumor progression remains largely unclear.
Lian Zhang, Yujiao He, Yi Jiang, Qi Wu, Yanchen Liu, Qing-Qiang Xie, Yuxiu Zou, Jiaqian Wu, Chun-Dong Zhang, Zhongjun Zhou, X. Bian, G. Jin   +11 more
semanticscholar   +1 more source

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins [PDF]

, 2009
Background: Despite the extensive genetic diversity of HIV-1, viral evolution in response to immune selective pressures follows broadly predictable mutational patterns. Sites and pathways of Human Leukocyte-Antigen (HLA)-associated polymorphisms in HIV-1
Haubrich, R., Riddler, SA, Richard Haubrich, John, Mina, Brumme, Z.L., Brumme, CJ, Swenson, L.C., Frahm, N., Riddler, S.A., Harrigan, P.R., David Heckerman, Brumme, Chanson J., Walker, B.D., Sela, J, Haas, DW, Kadie, Carl M., Jennifer Sela, Brockman, MA, Szeto, S., Kadie, Carl M, Luke C Swenson, Szeto, Sharon, John, M., Nicole Frahm, Brumme, Zabrina L., Brumme, Zabrina L, Simon Mallal, Haubrich, R, Harrigan, PR, Haas, D.W., John, M, Mallal, Simon, Szeto, S, Carlson, JM, Chan, Dennison, Swenson, LC, Kadie, CM, Swenson, Luke C., Tao, I., Harrigan, P Richard, Brumme, ZL, Jonathan M Carlson, Pamela Rosato, Tao, Iris, Riddler, Sharon A, Mallal, S., Rosato, P., Sela, Jennifer, Chanson J Brumme, Sharon A Riddler, Carlson, Jonathan M, Carlson, Jonathan M., Carlson, J.M., Brumme, C.J., Brumme, Chanson J, Carl M Kadie, Nixon, D.F., Brander, Christian, Bruce D Walker, Haubrich, Richard, Walker, Bruce D., Chan, D., Heckerman, D., Brockman, Mark A., Swenson, Luke C, Christian Brander, Iris Tao, Harrigan, P. Richard, Brockman, M.A., Sharon Szeto, David W Haas, Riddler, Sharon A., Chan, D, Walker, BD, P Richard Harrigan, Haas, David W., Rosato, P, Heckerman, David, Zabrina L Brumme, Frahm, N, Brander, C, Mark A Brockman, Brander, C., Heckerman, D, Sela, J., Tao, I, Rosato, Pamela, Dennison Chan, Frahm, Nicole, Mina John, Haas, David W, Walker, Bruce D, Brockman, Mark A, Mallal, S, Kadie, C.M.   +94 more
core   +2 more sources

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

Nature Communications, 2023
Association with hypomethylating agents is a promising strategy to improve the efficacy of immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation trial in patients with advanced melanoma of the hypomethylating agent ...
Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Roberta Mortarini, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf H. Fridman, Catherine Sautès-Fridman, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Rossella Tufano, Davide Bedognetti, Andrea Anichini, Michele Maio, Michele Ceccarelli   +18 more
doaj   +1 more source

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy

Frontiers in Oncology, 2021
Tumor immune escape refers to the phenomenon in which tumor cells escape the recognition and attack of the body’s immune system through various mechanisms so that they can survive and proliferate in vivo.
Wenxiang Zhang, Xiangyi Kong, Bolun Ai, Zhongzhao Wang, Xiangyu Wang, Nianchang Wang, Shan Zheng, Yi Fang, Jing Wang   +8 more
doaj   +1 more source

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Molecular Cancer, 2019
Tumor immune escape is an important strategy of tumor survival. There are many mechanisms of tumor immune escape, including immunosuppression, which has become a research hotspot in recent years. The programmed death ligand-1/programmed death-1 (PD-L1/PD-
Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Jun-Shang Ge, Bo Xiang, Xu Wu, Jian Ma, Ming Zhou, Xiao-Ling Li, Yong Li, Gui-yuan Li, W. Xiong, Can Guo, Z. Zeng   +14 more
semanticscholar   +1 more source

PPARγ inhibited tumor immune escape by inducing PD‐L1 autophagic degradation

Cancer Science, 2023
Blockade of the programmed death 1 (PD‐1)/ programmed death ligand 1 (PD‐L1) immune checkpoint could increase antitumor immunotherapy for multiple types of cancer, but the response rate of patients is about 10%–40%.
Qian Gou, Suning Che, Ming-Jun Chen, Hui-Qing Chen, Juanjuan Shi, Yongzhong Hou   +5 more
semanticscholar   +1 more source

Autophagy in tumor immune escape and immunotherapy

Molecular Cancer
The immunotherapy targeting tumor immune escape mechanisms has become a critical strategy in anticancer treatment; however, the challenge of immune resistance remains significant.
Huang Wang, Peng Sun, Xijing Yuan, Zhiyong Xu, Xinyuan Jiang, Mingshu Xiao, Xin Yao, Yue-Lin Shi   +7 more
semanticscholar   +1 more source